news
Canadian and US developers to trial psychedelic medicines in UK
Canadian and US developers of psychedelic medicines for complex mental health conditions have signed with a UK-based CMO to trial their drugs in London.
List view / Grid view
Addiction
article
Realising the therapeutic potential of MDMA
Psychedelic drugs are gaining popularity in the pharmaceutical R&D sector because of their apparent benefits for people suffering with neuropsychiatric disorders - and those which are resistant to existing therapies in particular. In this article, Imperial College London’s Professor David Nutt discusses the evidence underlying the development of psychedelic therapies…
news
Positive effects of psychedelic microdosing likely due to placebo effect, finds study
The largest placebo-controlled psychedelics study to date concluded that the psychological benefits of microdoses of psychedelics are likely due to the placebo effect.
news
Partnership to develop a microneedle patch for delivering psychedelic pharmaceuticals
The Terasaki Institute is partnering with PharmaTher to adapt a microneedle drug delivery patch for the micro-dosing of psychedelics.
news
Safety warnings for opioid medicines in UK to be added to labels
Warnings about addiction will be added to the patient information leaflets of opioids, the MHRA has announced.
news
Metformin may help with nicotine withdrawal
A drug that has helped millions of people around the world manage their diabetes may also help people ready to kick their nicotine habits...
